#MBRX

Trade Alerts, Monday January 12, 2026 – Crystal Equity Research

2 months ago

Small-cap stocks with improving money flow, Mon Jan 12th - #OKYO #HGBL #WLFC #SIFY #PLTS #MBRX #LYRA #IVA #EVTV #CPSH #BRNS #ADTN #EEX #CLW - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs Moleculin (Nasdaq: MBRX) outlined 2026–2028 clinical milestones for its anthracycline Annamycin and STAT3 inhibitor WP1066. The pivotal Phase 2B/3 MIRACLE trial for relapsed/refractory AML has expanded to nine countries with >46 sites selected and ~20 sites contracted, and is on track to treat the 45th Part A subject in Q1 2026 with an unblinding shortly thereafter and a second unblinding in Q3 2026. Part A targets 90 subjects; Part B will add 222 subjects. Institutional/externally funded trials include a 2026 Atlantic Health pancreatic trial and investigator‑initiated WP1066 trials at Northwestern and Emory. Primary MIRACLE efficacy data and a rolling NDA are targeted in 2028.

2 months ago

#MBRX Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

www.stocktitan.net/news/MBRX/moleculin-acce...

0 0 0 0

2 months ago

NEWS: ( NASDAQ: #MBRX ) Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

0 0 0 0

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight WP1066 found

2 months ago

#MBRX Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

www.stocktitan.net/news/MBRX/moleculin-anno...

0 0 0 0

2 months ago

Just In: ( NASDAQ: #MBRX ) Buy Recommendation Issued On MBRX By Roth Capital

0 0 0 0

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds Moleculin (Nasdaq: MBRX) announced agreements for immediate exercise of existing warrants to purchase an aggregate of 1,044,329 shares of common stock (727,969 shares issued Feb 2025 at $6.63; 316,360 shares issued Aug 2025 at $6.3219).The aggregate gross proceeds are expected to be approximately $6.5 million before advisory fees. In exchange, the company will issue new unregistered warrants exercisable for up to 2,610,823 shares at $6.63 per share, exercisable upon shareholder approval for a term of five years. Transaction expected to close on or about Dec 11, 2025, subject to customary closing conditions. Roth Capital Partners and Maxim Group are financial advisors.

3 months ago

#MBRX Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

www.stocktitan.net/news/MBRX/moleculin-anno...

0 0 0 0

3 months ago

Breaking News: ( NASDAQ: #MBRX ) Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026

0 0 0 0

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 Moleculin Biotech, Inc., (Nasdaq: MBRX)

3 months ago

#MBRX Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

www.stocktitan.net/news/MBRX/moleculin-anno...

0 0 0 0

3 months ago

NEWS: ( NASDAQ: #MBRX ) Moleculin Announces New Annamycin Collaboration in Brain Tumors

0 0 0 0

Moleculin Announces New Annamycin Collaboration in Brain Tumors Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a

3 months ago

#MBRX Moleculin Announces New Annamycin Collaboration in Brain Tumors

www.stocktitan.net/news/MBRX/moleculin-anno...

0 0 0 0

Trade Alerts, Wednesday November 26, 2025 – Crystal Equity Research

3 months ago

Small-cap stocks gapping down in trading, Wed Nov 26th - #MURA #CIFRW #ARTL #SNT #MBRX #KXIN #GORV #ALAR #PD - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Moleculin Announces Reverse Stock Split Moleculin (Nasdaq: MBRX) filed an amendment to its certificate of incorporation to effect a 1-for-25 reverse stock split of its common stock, effective 12:01 am ET on December 1, 2025. The company said shares will open for trading on Nasdaq on December 1, 2025 on a post-split basis under the existing ticker MBRX but with a new CUSIP 60855D 408. Every 25 pre-split shares will be consolidated into one share, with no change to the $0.001 par value. Fractional shares will not be issued; holders entitled to fractions will receive a cash payment in lieu. Outstanding shares are expected to fall from approximately 51.7 million to approximately 2.1 million, while authorized shares remain 500 million.

3 months ago

#MBRX Moleculin Announces Reverse Stock Split

www.stocktitan.net/news/MBRX/moleculin-anno...

0 0 0 0

Trade Alerts, Monday November 24, 2025 – Crystal Equity Research

3 months ago

Small-cap stocks gapping down in trading, Mon Nov 24th - #FRGT #MBRX #CLSD #CHR - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today provided

4 months ago

#MBRX Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

www.stocktitan.net/news/MBRX/moleculin-repo...

0 0 0 0

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill Moleculin

4 months ago

#MBRX Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

www.stocktitan.net/news/MBRX/moleculin-anno...

0 0 0 0

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting Moleculin (Nasdaq: MBRX) will present at the 14th Annual Acute Leukemia Meeting in Madrid on October 30-31, 2025. Dr. Paul Waymack, senior chief medical officer, will speak on Thursday, October 30 at 2:35 PM CEST about L-Annamycin (naxtarubicin) and the ongoing pivotal Phase 2B/3 “MIRACLE” trial.The MIRACLE study is a multi-center, randomized, double-blind, placebo-controlled, adaptive design trial evaluating Annamycin combined with cytarabine (AnnAraC) in adult patients with relapsed or refractory acute myeloid leukemia (R/R AML). It is a global approval trial with sites in the US, Europe and the Middle East (clinicaltrials.gov NCT06788756; euclinicaltrials.eu 2024-518359-47-00). Annamycin currently holds FDA Fast Track status and Orphan Drug designations from FDA and EMA for R/R AML.

4 months ago

#MBRX Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

www.stocktitan.net/news/MBRX/moleculin-to-h...

0 0 0 0

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin Moleculin (Nasdaq: MBRX) announced that IP Australia granted Patent No. 2024203598 titled "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE", covering preliposomal Annamycin lyophilizates with improved stability and high purity.The patent has a base term currently extending until June 2040, subject to extension to account for regulatory approval time, and expands the company's global IP portfolio alongside an expected Canadian patent and previously issued U.S. and allowed European patents. Annamycin (naxtarubicin) has FDA Fast Track Status and Orphan Drug Designation for relapsed/refractory AML and Orphan Drug Designation for STS lung mets; EMA orphan status for relapsed/refractory AML is also noted.

4 months ago

#MBRX Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

www.stocktitan.net/news/MBRX/moleculin-expa...

0 0 0 0

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer Moleculin (NASDAQ:MBRX) is collaborating with Atlantic Health on an investigator-initiated Phase 1B/2 single-arm study testing Annamycin for third-line (3L) advanced pancreatic cancer, announced Oct 23, 2025. Moleculin will supply drug material and maintain the IND; Atlantic Health will conduct and fund the study. Moleculin estimates incremental trial costs of approximately $1 million from 2026 into 2030 for drug supply and outside lab testing. Preclinical data show pancreatic uptake, activity vs pancreatic tumors and liver metastases, and topoisomerase II as a validated target. Annamycin has FDA Fast Track and multiple Orphan Drug designations.

4 months ago

#MBRX Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

www.stocktitan.net/news/MBRX/moleculin-anno...

0 0 0 0

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin Moleculin Biotech (Nasdaq: MBRX) has received a notice of allowance from the Canadian Intellectual Property Office for a patent covering their novel drug candidate Annamycin. The patent, extending until June 2040, will protect methods of making preliposomal Annamycin lyophilizate with improved stability and high purity.Annamycin is positioned to become the first non-cardiotoxic anthracycline for approval, targeting acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases. The drug has received Fast Track Status and Orphan Drug Designation from both FDA and EMA for various indications.

5 months ago

#MBRX Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

www.stocktitan.net/news/MBRX/moleculin-anno...

0 0 0 0

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial Moleculin Biotech (Nasdaq: MBRX) reported significant progress in its Phase 3 "MIRACLE" clinical trial for Annamycin in combination with cytarabine (AnnAraC) for treating acute myeloid leukemia (AML). The company has recruited 13 subjects (10 already dosed) and expects to reach 20 subjects by September 2025.The trial is expanding globally across multiple European countries and the US, with plans to increase from 12 to 20 active sites in September, and over 30 sites by year-end. The company aims to recruit the 45th subject in Q4 2025 for initial data unblinding, with Part A completion expected in H1 2026.The MIRACLE study employs an adaptive design with 75-90 subjects in Part A and approximately 220 additional subjects in Part B. Annamycin currently holds Fast Track Status and Orphan Drug Designation from both FDA and EMA.

6 months ago

#MBRX Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

www.stocktitan.net/news/MBRX/moleculin-acce...

0 0 0 0

$6 Million Cash Infusion: Moleculin Biotech Executes Strategic Warrant Deal with 64.8M New Warrants Late-stage pharma Moleculin (MBRX) raises $6M via warrant exercise at $0.37/share, issues new warrants for 64.8M shares at $0.55. Funds targeted for working capital and corporate purposes.

6 months ago

#MBRX Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

www.stocktitan.net/news/MBRX/moleculin-anno...

0 0 0 0

6 months ago

Charts of the Day - small-cap stocks forming bullish engulfing candlestick signal, Thu Aug 27th - #APRE #MBRX - More: crystalequityresearch.com/charts-of-th... - #smallcap

0 0 0 0

Moleculin Issues New Positive AML Overall Survival Data: Moleculin Biotech (Nasdaq: MBRX) has announced significant positive survival data from its Phase 1B/2 (MB-106) clinical trial of Annamycin combined with Cytarabine (AnnAraC) for acute myeloid leukemia (AML) treatment. The trial demonstrated remarkable median overall survival rates: 15 months for complete remission subjects (n=8), 12 months for 2nd line patients (n=9), and 9 months for the intent-to-treat population (n=22).Key achievements include a 36% complete remission rate in the total population and a 50% CR rate in second-line patients. Notably, 50% of CR patients proceeded to bone marrow transplant. The treatment showed no cardiotoxicity, with median CR durability of 10 months. The company expects database lock by September 2025 and final clinical study report in Q1 2026.Moleculin continues to advance Part A of its pivotal Phase 3 MIRACLE trial, targeting recruitment of 45 patients by year-end 2025.

6 months ago

#MBRX Moleculin Issues New Positive AML Overall Survival Data:

www.stocktitan.net/news/MBRX/moleculin-issu...

0 0 0 0

Moleculin Reports Second Quarter 2025 Financial Results and Highlights Moleculin Biotech (Nasdaq: MBRX) reported Q2 2025 financial results and significant progress in its clinical trials. The company's flagship Phase 2B/3 MIRACLE trial for Annamycin in treating relapsed/refractory AML is expanding, with 4 active sites and 20+ additional sites expected in Q3 2025. The trial's first data readout is anticipated by end of 2025.Key developments include positive topline results from the Phase 1B/2 trial for soft tissue sarcoma lung metastases, showing 13.5-month median overall survival. The company reported $7.6 million in cash, sufficient to fund operations into Q4 2025. R&D expenses decreased to $3.6 million from $4.1 million year-over-year, while G&A expenses remained stable at $2.1 million. [ "Expansion of MIRACLE trial with 4 active sites and 20+ additional sites expected by Q3 2025", "Positive FDA feedback received on pediatric AML study plan", "Encouraging preclinical data for Annamycin against liver cancers", "Strong Phase 1B/2 results showing 13.5-month median overall survival in STS lung mets trial", "New European patent strengthening intellectual property portfolio" ]

7 months ago

#MBRX Moleculin Reports Second Quarter 2025 Financial Results and Highlights

www.stocktitan.net/news/MBRX/moleculin-repo...

0 0 0 0

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment Moleculin Biotech (NASDAQ:MBRX) has presented promising preclinical data for its lead drug candidate Annamycin in treating various liver cancers. The drug demonstrated significant efficacy against hepatocellular carcinoma (HCC), colorectal liver metastases, and pancreatic ductal adenocarcinoma (PDAC) liver metastases.Key findings show that Annamycin achieves higher concentrations in the liver, spleen, lungs, and pancreas compared to doxorubicin. The drug exhibited strong anti-tumor activity in multiple cancer models while maintaining a favorable safety profile with low or no cardiotoxicity. Notably, 32 out of 42 subjects previously received above FDA's lifetime maximum allowable anthracycline level without cardiotoxicity evidence.Annamycin is currently in late-stage clinical development for AML treatment, with preliminary data expected in 2H 2025.

7 months ago

#MBRX Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

www.stocktitan.net/news/MBRX/moleculin-biot...

0 0 0 0